Rifabutin[2]
Overview
Rifabutin is a semisynthetic ansamycin antibiotic derived from rifamycin S, first approved by the FDA in 1992. It belongs to the rifamycin class and shares structural similarities with rifampin, though with distinct pharmacokinetic properties. The compound is particularly valued for its activity against atypical mycobacteria, including Mycobacterium avium complex (MAC), making it a critical agent in immunocompromised patients. As a DNA-dependent RNA polymerase inhibitor, rifabutin disrupts bacterial transcription. Its broader spectrum and longer half-life compared to rifampin allow for less frequent dosing. The drug is classified as a BCS Class II substance (low solubility, high permeability) and is typically administered orally in capsule form.
Physical and Chemical Properties
Rifabutin appears as a reddish-brown crystalline powder with limited aqueous solubility but good solubility in organic solvents like chloroform. Its molecular structure includes a naphthoquinone chromophore responsible for the characteristic color. The compound is sensitive to light and oxidization, requiring amber glass containers for storage. Thermogravimetric analysis shows decomposition beginning at 160°C without a distinct melting point. The logP value of approximately 3.5 indicates moderate lipophilicity, which contributes to its tissue penetration. In solution, rifabutin exhibits pH-dependent stability, with optimal preservation in slightly acidic conditions (pH 4-6).
Main Applications
The primary clinical use of rifabutin is for prophylaxis and treatment of Mycobacterium avium complex infections in HIV-positive patients. It's also employed as part of combination therapy for multidrug-resistant tuberculosis when first-line drugs cannot be used. Off-label applications include Helicobacter pylori eradication regimens and treatment of other nontuberculous mycobacterial infections. In research contexts, rifabutin serves as a selective agent for studying bacterial RNA polymerase mutations. Its unique pharmacokinetic profile—including extensive tissue distribution and intracellular accumulation—makes it valuable for investigating macrophage-targeted antimicrobial therapies. Veterinary applications are limited but include certain mycobacterial infections in animals.
Safety and Storage
Rifabutin requires careful handling due to its potential to cause orange discoloration of body fluids (tears, urine, sweat) and possible staining of contact lenses. Hematologic monitoring is recommended during prolonged therapy as leukopenia may occur. As a strong CYP3A4 inducer, it participates in numerous drug-drug interactions requiring dose adjustments. For storage, maintain original containers at controlled room temperature (15-30°C) or refrigerated (2-8°C) for long-term preservation. Protect from humidity and light exposure. Shelf life typically ranges from 24-36 months when properly stored. Decomposition products may show reduced antibacterial activity and increased toxicity.
B2B Procurement Guide
Pharmaceutical-grade rifabutin should be sourced from GMP-certified manufacturers with documented quality control processes. Key procurement considerations include batch-to-batch consistency in purity (>98% by HPLC), residual solvent levels (meeting ICH Q3C guidelines), and microbiological testing for sterile applications. Bulk buyers should request full analytical documentation including 1H NMR spectra, mass spectrometry data, and dissolution profiles. Pricing varies significantly by quantity (gram to kilogram scale) and purity specifications. For research use, small quantities (1-10g) are commonly available through specialty chemical distributors with lead times of 2-4 weeks. Large-scale pharmaceutical procurement may require contractual manufacturing agreements.